Aravive Inc (NASDAQ:ARAV) Expected to Announce Earnings of -$0.49 Per Share

Equities research analysts expect Aravive Inc (NASDAQ:ARAV) to announce earnings of ($0.49) per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Aravive’s earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.42). Aravive reported earnings per share of ($1.20) during the same quarter last year, which indicates a positive year-over-year growth rate of 59.2%. The firm is scheduled to issue its next quarterly earnings results on Thursday, March 5th.

According to Zacks, analysts expect that Aravive will report full year earnings of ($1.68) per share for the current year, with EPS estimates ranging from ($1.82) to ($1.47). For the next financial year, analysts anticipate that the business will report earnings of ($2.28) per share, with EPS estimates ranging from ($3.29) to ($1.47). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Aravive.

Aravive (NASDAQ:ARAV) last posted its earnings results on Thursday, November 7th. The company reported ($0.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.04).

Several brokerages recently weighed in on ARAV. Piper Jaffray Companies set a $15.00 price objective on shares of Aravive and gave the company a “buy” rating in a report on Friday, September 27th. ValuEngine upgraded shares of Aravive from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Zacks Investment Research lowered shares of Aravive from a “buy” rating to a “hold” rating in a report on Thursday, October 24th. Finally, HC Wainwright restated a “buy” rating on shares of Aravive in a report on Friday. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Aravive has a consensus rating of “Buy” and a consensus price target of $13.69.

In related news, CEO Jay Shepard sold 4,004 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $6.82, for a total value of $27,307.28. Corporate insiders own 39.80% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its holdings in Aravive by 13.8% in the second quarter. Renaissance Technologies LLC now owns 148,265 shares of the company’s stock valued at $890,000 after buying an additional 18,017 shares during the period. Vanguard Group Inc. lifted its holdings in Aravive by 4.7% in the second quarter. Vanguard Group Inc. now owns 159,034 shares of the company’s stock valued at $955,000 after buying an additional 7,200 shares during the period. BlackRock Inc. lifted its holdings in Aravive by 5.8% in the second quarter. BlackRock Inc. now owns 173,943 shares of the company’s stock valued at $1,044,000 after buying an additional 9,544 shares during the period. Finally, Artal Group S.A. lifted its holdings in Aravive by 20.0% in the second quarter. Artal Group S.A. now owns 307,466 shares of the company’s stock valued at $1,845,000 after buying an additional 51,197 shares during the period. Institutional investors and hedge funds own 28.35% of the company’s stock.

NASDAQ ARAV traded up $0.01 on Tuesday, reaching $6.53. The company’s stock had a trading volume of 5,300 shares, compared to its average volume of 23,717. The business has a 50-day moving average price of $7.03 and a 200 day moving average price of $6.27. Aravive has a 52 week low of $3.07 and a 52 week high of $9.72. The firm has a market cap of $75.95 million, a PE ratio of -0.61 and a beta of 2.17. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.17.

Aravive Company Profile

Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.

See Also: What is meant by holder of record?

Get a free copy of the Zacks research report on Aravive (ARAV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aravive (NASDAQ:ARAV)

Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.